Latest Newlink Genetics Corp (NLNK) Headlines B
Post# of 69
Posted On: 03/13/2014 12:18:11 AM
Latest Newlink Genetics Corp (NLNK) Headlines
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results
eTeligis - Tue Mar 11, 3:01PM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), today reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Alpha Natural Resources, NewLink Genetics, and Furmanite Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 7:30PM CST
On Friday, investors wrestled with nervousness about the rapidly changing situation in Russia and Ukraine, but the stock market eventually closed with small gains that sent the S&P 500 to all-time highs. Yet, many stocks failed to feel the...
Why NewLink Genetics Corp. Shares Plunged
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NewLink Genetics , a clinical-stage...
Risk of Pivotal Study Failure Rises for NewLink and Northwest Bio
at The Street - Fri Mar 07, 9:51AM CST
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
Morning Movers in Biotech: Gilead Sciences, NewLink Genetics Corp. and Novartis AG
George Budwell, The Motley Fool - Motley Fool - Fri Mar 07, 7:55AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
NewLink Genetics' Independent Review Committee Recommends Study Continuation Without Modification After Completion of First Interim Analysis of IMPRESS Phase 3 Pancreatic Cancer Trial With Algenpantucel-L
Marketwire - Fri Mar 07, 6:15AM CST
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the continuation of the Phase 3 IMPRESS clinical study of algenpantucel-L for patients with surgically resected pancreatic cancer following the first of two planned interim data analyses.
Why NewLink Genetics Corp. Shares Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 1:14PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NewLink Genetics , a clinical-stage...
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
NewLink Genetics Appoints Eugene P. Kennedy, M.D., as Vice President for Clinical and Medical Affairs
Marketwire - Wed Feb 26, 8:15AM CST
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the appointment of Eugene P. Kennedy, M.D., FACS, as Vice President for Clinical and Medical Affairs. Dr. Kennedy will be responsible for clinical operations related to NewLink's HyperAcute(R) and IDO (indoleamine-(2,3)-dioxygenase) pathway product candidates as well as supporting commercial development strategies. "We are delighted that Dr. Kennedy has joined our team," commented Nicholas Vahanian, M.D., Chief Medical Officer of NewLink. "I had the distinct pleasure of working with Gene during NewLink's Phase 2 pancreatic cancer trial with algenpantucel-L. He is a tremendously talented physician and we look forward to his many contributions to NewLink in the future. Gene's appointment aligns with our expanded clinical and commercial activities as NewLink's HyperAcute and IDO programs continue to advance in development."
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
NewLink Genetics (NLNK) Jumps: Stock Moves 8.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:46AM CST
NewLink Genetics was a big mover last session, with shares rising over 8%.
5 States Where Lung Cancer Rates Are the Highest
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 23, 12:05PM CST
There are few, if any, diagnoses scarier than cancer , primarily because it's a disease that has had billions of dollars thrown at it over the course of the past three decades, yet researchers, and we as a nation, are still very much in the dark as...
These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 1:05PM CST
Change typically doesn't hit the health care industry all at once, but in practically a blink of an eye, cancer immunotherapies -- training the body's immune system to recognize and attack cancer -- are all the rage. We can certainly point to the...
NewLink Genetics (NLNK) Jumps: Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:21AM CST
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 8% on the day.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Financial Results, Clinical Study Updates, Clinical Trial Results, Business Spin-Offs, and New Joint Ventures - Analyst Notes on ARIAD, NewLink, Puma Biotechnology, Theravance, and Ohr Pharmaceutical
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), NewLink Genetics Corporation (NASDAQ: NLNK), Puma Biotechnology, Inc. (NYSE: PBYI), Theravance, Inc. (NASDAQ: THRX), and Ohr Pharmaceutical, Inc. (NASDAQ: OHRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
NewLink Genetics Corporation Reports Fourth Quarter and Year End 2013 Financial Results
eTeligis - Tue Mar 11, 3:01PM CDT
NewLink Genetics Corporation (NASDAQ: NLNK), today reported consolidated financial results for the fourth quarter and year end 2013 and reviewed key 2013 accomplishments.
NewLink Genetics' Shares Sink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 12:36PM CDT
Share prices of NewLink Genetics fell 16.2% after the committee recommended continuation of its phase III pancreatic cancer study (IMPRESS) of HyperAcute Pancreas.
This Week in Biotech: Put It in Print
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 08, 1:05PM CST
With the SPDR S&P Biotech Index up 62% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Why Alpha Natural Resources, NewLink Genetics, and Furmanite Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 07, 7:30PM CST
On Friday, investors wrestled with nervousness about the rapidly changing situation in Russia and Ukraine, but the stock market eventually closed with small gains that sent the S&P 500 to all-time highs. Yet, many stocks failed to feel the...
Why NewLink Genetics Corp. Shares Plunged
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NewLink Genetics , a clinical-stage...
Risk of Pivotal Study Failure Rises for NewLink and Northwest Bio
at The Street - Fri Mar 07, 9:51AM CST
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
Morning Movers in Biotech: Gilead Sciences, NewLink Genetics Corp. and Novartis AG
George Budwell, The Motley Fool - Motley Fool - Fri Mar 07, 7:55AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
NewLink Genetics' Independent Review Committee Recommends Study Continuation Without Modification After Completion of First Interim Analysis of IMPRESS Phase 3 Pancreatic Cancer Trial With Algenpantucel-L
Marketwire - Fri Mar 07, 6:15AM CST
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the continuation of the Phase 3 IMPRESS clinical study of algenpantucel-L for patients with surgically resected pancreatic cancer following the first of two planned interim data analyses.
Why NewLink Genetics Corp. Shares Swooned
Sean Williams, The Motley Fool - Motley Fool - Mon Mar 03, 1:14PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of NewLink Genetics , a clinical-stage...
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
NewLink Genetics Appoints Eugene P. Kennedy, M.D., as Vice President for Clinical and Medical Affairs
Marketwire - Wed Feb 26, 8:15AM CST
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, today announced the appointment of Eugene P. Kennedy, M.D., FACS, as Vice President for Clinical and Medical Affairs. Dr. Kennedy will be responsible for clinical operations related to NewLink's HyperAcute(R) and IDO (indoleamine-(2,3)-dioxygenase) pathway product candidates as well as supporting commercial development strategies. "We are delighted that Dr. Kennedy has joined our team," commented Nicholas Vahanian, M.D., Chief Medical Officer of NewLink. "I had the distinct pleasure of working with Gene during NewLink's Phase 2 pancreatic cancer trial with algenpantucel-L. He is a tremendously talented physician and we look forward to his many contributions to NewLink in the future. Gene's appointment aligns with our expanded clinical and commercial activities as NewLink's HyperAcute and IDO programs continue to advance in development."
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
NewLink Genetics (NLNK) Jumps: Stock Moves 8.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 8:46AM CST
NewLink Genetics was a big mover last session, with shares rising over 8%.
5 States Where Lung Cancer Rates Are the Highest
Sean Williams, The Motley Fool - Motley Fool - Sun Feb 23, 12:05PM CST
There are few, if any, diagnoses scarier than cancer , primarily because it's a disease that has had billions of dollars thrown at it over the course of the past three decades, yet researchers, and we as a nation, are still very much in the dark as...
These 5 Cancer Immunotherapy Companies All Have 1 Thing in Common
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 18, 1:05PM CST
Change typically doesn't hit the health care industry all at once, but in practically a blink of an eye, cancer immunotherapies -- training the body's immune system to recognize and attack cancer -- are all the rage. We can certainly point to the...
NewLink Genetics (NLNK) Jumps: Stock Rises 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:21AM CST
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 8% on the day.
(0)
(0)Lumos Pharma, Inc. (LUMO) Stock Research Links
Scroll down for more posts ▼